Research programme: protease inhibitors - Polyphor

Drug Profile

Research programme: protease inhibitors - Polyphor

Latest Information Update: 15 Mar 2013

Price : $50

At a glance

  • Originator Polyphor
  • Class Peptides; Small molecules
  • Mechanism of Action Cysteine endopeptidase inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Asthma

Most Recent Events

  • 01 Mar 2013 Preclinical trials in Cystic fibrosis in Switzerland (Inhalation)
  • 01 Mar 2013 Preclinical trials in Alpha 1-antitrypsin deficiency in Switzerland (Inhalation)
  • 01 Feb 2012 Discontinued for Asthma in Switzerland (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top